Roche (RHHBY) expects an increase in Group sales in the mid single digit range. Core earnings per share are targeted to develop in the high single to low double digit range. Roche expects to further increase its dividend in Swiss francs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Trump Trade: Trump administration prepares new probe into pharma prices
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Celcuity price target raised to $95 from $70 at Needham
- Oppenheimer remains bullish on Olema despite ‘Jekyll and Hyde kinda ESMO’
- Genentech announces FDA approval for Gazyva for active lupus nephritis